PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of advhematolAdvances in Hematology
 
Adv Hematol. 2011; 2011: 142395.
Published online 2010 October 24. doi:  10.1155/2011/142395
PMCID: PMC2963118

Hodgkin's Lymphomas: A Tumor Recognized by Its Microenvironment

Abstract

Thomas Hodgkin's and Samuel Wilks first recognized Hodgkin disease in the first half of the 19th century. Initially described as lymphogranulomatosis, it was later recognized to be a lymphoid neoplasm derived from B cells and was classified on the basis of its histopathological features. Hodgkin lymphomas are now regarded as encompassing two clearly defined entities according to the WHO classification: nodular lymphocyte-predominant Hodgkin Lymphoma (NLPHL) and classical Hodgkin Lymphoma (CHL). This paper focuses on the current knowledge about the biological features that characterize both NLPHL and CHL, highlighting those relevant to correct pathological diagnosis and those that might be associated with patient outcome.

1. Introduction

Hodgkin's disease was first recognized in the first half of the 19th century by Hodgkin [1] and Wilks [2, 3]. Initially described as lymphogranulomatosis, it was later recognized as being a lymphoid neoplasm derived from B cells and classified following the Lukes-Butler scheme [4, 5] on the basis of its histopathological features. This pathological classification was identified early on as the main prognostic marker since the nature of the reactive infiltrate or microenvironment reflected the host response and thus, prognosis [4, 6]. Nowadays Hodgkin's lymphomas is regarded as encompassing two clearly defined entities according to the WHO classification: nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) and classical Hodgkin lymphoma (CHL) [710]. These two entities differ in clinical features and behaviour but, more importantly, in the pathological and biological features of their neoplastic and microenvironmental compartments.

The differences in the biological features of the tumours are routinely used in the pathological diagnosis of patients with HL [7, 11] but they can also be exploited as biomarkers of prognosis. This paper focuses on our current knowledge of the biological features that characterize both NLPHL and CHL, highlighting those relevant to correct pathological diagnosis and those that might be associated with patient outcome.

2. NLPHL: Usefulness of the Microenvironment in Diagnosis

Nodular lymphocyte-Predominant Hodgkin lymphoma accounts for approximately 5% of all Hodgkin's lymphomas. This type is characterized clinically by a relatively indolent course, a very good response to standard therapies in cases with low-stage disease, but an unfavourable prognosis for advanced stages [9, 12]. Rates of progression to large B cell lymphoma (commonly Diffuse Large B Cell lymphoma (DLBCL), rarely T cell/Histiocyte Rich-like B cell lymphoma (T/HRBCL)) vary according to the series, with a range between 3%–12% of cases [1216].

Biologically, NLPHL is a Germinal Centre-(GC-)derived B cell neoplasm [17, 18] that retains an almost complete B Cell program at the transcriptional [19] and phenotypic [8, 20] levels. The characteristic lymphocyte-Predominant (LP) cells exhibit a GC phenotypic profile with expression of GC markers such as BCL6 [11, 21], GCET1 [22] and LMO2 [23], together with expression of transcription factors related to a sustained B cell program such as Oct-2 and BOB.1. Interestingly, the GC-related profile is seen not only in LP cells but also in the surrounding T cells, which characteristically create a rosette-like pattern typical of NLPHL (Figure 1). These rosetting T cells have a Follicular T cell phenotype with expression of CD3/CD4/CD57 [24], bcl6 [21], PD1 [20, 25] and, interestingly, CXCL13, a chemokine that is known to induce B cell homing to lymphoid follicles and that plays a role in the T cell-dependent B cell affinity maturation process [26]. These observations suggest that NLPHL is characterized by a GC phenotype in both LP and T cells. This combination is not found in classical HL (CHL), with the exception of lymphocyte-Rich CHL. In fact, this particular subtype of CHL has a profile intermediate between those of NLPHL and CHL with overexpression of B cell transcription program markers and the presence of a follicular T cell background in a substantial proportion of cases [27] (Figure 1). This is not the case for the other types of CHL in which the B cell program and the germinal centre microenvironment are lost. It is remarkable that this previously described immunohistological pattern (i.e., rosettes of Follicular T cells surrounding large B cells) can also be exploited in the differential diagnosis of NLPHL and T/HRBCL, especially in cases whose morphological features overlap [11, 20, 28].

Figure 1
NLP-HL: HE section of a case of Nodular lymphocyte-predominant Hodgkin lymphoma, showing a typical lymphocyte-Predominant (LP) cell positive for CD20 (NLP-CD20) and surrounded by a rim of PD1-positive T cells (NLP-PD1). LR-CHL: HE section of a case of ...

3. Classical Hodgkin Lymphoma (CHL): The Microenvironment as a Prognostic Marker

CHL accounts for 95% of all Hodgkin's lymphomas. This type is characterized by a relative paucity of Reed-Sternberg and Hodgkin neoplastic cells in a background of mixed inflammatory infiltrate by histiocytes, small lymphocytes, eosinophils, neutrophils, plasma cells, fibroblasts and collagen. Depending on the particular combinations of these elements and the specific features of the neoplastic cells, cases may be subclassified into one of four subtypes: nodular sclerosis, mixed cellularity, lymphocyte-rich and lymphocyte-depleted [7]. Initially considered the best predictor of clinical outcome in CHL [4, 6] histological classification per se has lost its predictive power, mainly due to the considerable advances in therapeutic regimens [2931]. These therapeutic improvements have transformed CHL into a curable disease in more than 85% of cases. However, a considerable percentage of patients still fail to respond successfully to current standard therapies. Early identification of these cases has become the main objective of clinical and biological research. In the clinical field it has become apparent that early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is a good marker of prognosis and could be used for planning risk-adapted treatment in advanced HL [32]. In the biological field, the extensive study of pathways involved in HL pathogenesis has identified apoptosis deregulation and constitutive NFκB activity as being the factors mainly responsible for tumor unrestricted growth [17, 29, 33]. In particular, constitutive NFκB signalling has been implicated in the activation of upstream receptors [3438] and in several genetic lesions affecting the NFκB pathway [3945].

Together with genetic lesions affecting the neoplastic population, this malignant component is also tightly regulated by interactions with the microenvironment. Of particular interest is the presence of biased T cell populations in HL cases, evidence for a disregulation of T cell immune function. In this sense, a considerable fraction of infiltrating CD4+ T cells are regulatory (Treg) cells which have been shown to display immunosuppressive activity on HL Th2 cells [46]. It has been also shown that together with T regs (recruited due to the secretion of galectin-1 [47, 48]), PD1+ T cells interact with Hodgkin and R-S cells as outlined in the previous section [20, 27, 46, 52, 55]. It has been clearly demonstrated that neoplastic HL cells express PD1-L genes B7-H1 and B7-DC and this expression is induced by EBV latent membrane proteins. Blockade of this immunological synapse leads to restoration of IFNγ production by CD4+ T cells in the microenvironment of HL cases and to inhibition of the phophorilation of SHP-2, a mediator of the PD1 signalling pathway. Thus the expression of PD1L genes by HL cells may sustain this immunological synapse that leads to inhibition of IFNγ production by TCD4 cells [52]. Blockade of this crosstalk leads to the recovery of T cell antitumoral function thus providing a basis for immunotherapy of HL [56, 57] (Figure 2).

Figure 2
The HRS cell and its cellular microenvironment. Significant interactions with impact in patients outcome are depicted. Increased Galectin1 and IL-10 secreted by HRS (Hodgkin and Reed-Sternberg) cells lead to decreased TCL (T cytotoxic) and Th1 responses, ...

4. Translational Biology in CHL

The knowledge based on the biology of CHL has recently become of potential clinical application after the generation of prognostic models of the expression of many of these biological markers. In two very recent papers [58, 59] genome-wide analysis of CHL cases was used to identify gene signatures associated with clinical outcome. These particular gene signatures were validated in routinely processed Formalin-Fixed Paraffin-Embedded (FFPE) samples using RT-PCR [58] or Immunohistochemistry [59], which are both techniques that could be implemented in clinical laboratories.

In the study by Sanchez-Espiridion et al. [58] genes were selected on the basis of previous data published by the same group [53] who identified genes involved in the regulation of mitosis and cell growth/apoptosis (TOP2A, RRM2, PCNa, MAD2L1 and CDC2), those expressed by the tumoral cells (as demonstrated by the use of HL cell lines as control), and genes expressed by the microenvironmental compartment (including those expressed by monocyte/macrophages STAT1, ALDH1A1) and T cells (SH2D1A). This particular set of genes was validated by immunohistochemistry in the same series of patients and has recently been confirmed in a new independent retrospective series of HL patients using Real-time PCR [58]. Apoptosis-related genes (BCL2, BCL2L1, CASP3) and cell cycle-associated transcripts (CCNA1, CDC2, CCNA2) are among the markers with confirmed prognostic value, and may provide a rational basis for the use of new therapeutic agents targeting pathways in patients with advanced or refractory CHL.

Interestingly, among the pathways associated with worse outcome in CHL in the study by Sánchez-Aguilera et al. [53] monocyte/macrophages prove to be a major determinant of outcome, a finding confirmed in the series of Steidl et al. [59]. These authors identified a gene signature of tumor-associated macrophages that was significantly associated with primary treatment failure. They validated their findings immunohistochemically by quantifying the presence of C68+ macrophages in diagnostic samples, demonstrating that the higher the content of macrophages in the biopsy the greater the risk of progression after primary treatment and relapse following autologous stem-cell transplantation. On the other hand, patients with limited-stage disease and without elevated numbers of CD68+ cells had a long-term disease-specific survival of 100% using current treatment strategies. These data provide further support for the hypothesis that specific tumor microenvironmental components can be used as markers of prognosis in patients with CHL. These results suggests new possibilities for specific therapies that target these cellular components and could be used as adjuvant therapy in patients with poor outcome. Conversely, better identification of good outcome patients at diagnosis could avoid unnecessary overtreatment.

5. Conclusions

The molecular dissection of Hodgkin's lymphomas using transcriptional profiling and detailed phenotypic analysis has expanded our view of Hodgkin lymphoma as a disease. First, it has clarified the current classification, establishing NLPHL as a different disease entity from CHL [7] and identifying new markers that can be used in routine practice for this differential diagnosis and with other disease entities. Second, it confirms in a very sophisticated way the pioneer reports [6062] that assigned to specific microenvironmental cellular components (i.e., macrophages) a role as biomarkers of patient outcome, simultaneously identifying potential new treatment strategies.

References

1. Hodgkin T. On some morbid appearances of the absorbent glans and spleen. Medico-Chirurgical Transactions. 1832;17:68–117. [PMC free article] [PubMed]
2. S. Wilks. Cases of lardaceous disease and some allied affections, with remarks. Guy’s Hospital Reports. 1856;17(2):103–132.
3. Wilks S. Enlargement of the lymphatic glands and spleen (or, Hodgkin’s disease) with remarks. Guy’s Hospital Reports. 1856;11:56–67.
4. Lukes RJ, Hicks E. Natural History of Hodgkin’s disease as related to its pathological picture. Cancer. 1966;19:317–344.
5. Lukes RJ, Hall T, Rappaport H, Ruben P. Report of the nomenclature comittee. Cancer Research. 1966;26:1311–1313.
6. Rapaport SI. Introduction to Hematology. New York, NY, USA: Harper & Row; 1974.
7. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tisues. 4th edition. Lyon, France: IARC Press; 2008.
8. Mason DY, Banks PM, Chan J, et al. Nodular lymphocyte predominance Hodgkin’s disease. A distinct clinicopathological entity. American Journal of Surgical Pathology. 1994;18(5):526–530. [PubMed]
9. Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte- predominant Hodgkin’s disease and lymphocyte-rich classical Hodgkin’s disease: report from the European Task Force on lymphoma project on lymphocyte-predominant Hodgkin’s disease. Journal of Clinical Oncology. 1999;17(3):776–783. [PubMed]
10. Nogová L, Reineke T, Brillant C, et al. Lymphocyte-predominant and classical Hodgkin’s lymphoma: a comprehensive analysis from the german Hodgkin study group. Journal of Clinical Oncology. 2008;26(3):434–439. [PubMed]
11. Fan Z, Natkunam Y, Bair E, Tibshirani R, Warnke RA. Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation. American Journal of Surgical Pathology. 2003;27(10):1346–1356. [PubMed]
12. Jackson C, Sirohi B, Cunningham D, Horwich A, Thomas K, Wotherspoon A. Lymphocyte-predominant Hodgkin lymphoma-clinical features and treatment outcomes from a 30-year experience. Annals of Oncology. 2010;21(10):2061–2068. [PubMed]
13. Biasoli I, Stamatoullas A, Meignin V, et al. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the adult lymphoma study group. Cancer. 2010;116(3):631–639. [PubMed]
14. Miettinen M, Franssila KO, Saxen E. Hodgkin’s disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin’s lymphomas. Cancer. 1983;51(12):2293–2300. [PubMed]
15. Hansmann M-L, Fellbaum C, Hui PK, Parwaresch MR, Lennert K. Nodular paragranuloma can transform into high-grade malignant lymphoma of B type. Human Pathology. 1989;20(12):1169–1175. [PubMed]
16. Rüdiger T, Gascoyne RD, Jaffe ES, et al. Workshop on the relationship between nodular lymphocyte predominant Hodgkin’s lymphoma and T cell/histiocyte-rich B cell lymphoma. Annals of Oncology. 2002;13(supplement 1):44–51. [PubMed]
17. Küppers R. The biology of Hodgkin’s lymphoma. Nature Reviews Cancer. 2009;9(1):15–27. [PubMed]
18. Marafioti T, Hummel M, Anagnostopoulos I, et al. Origin of nodular lymphocyte-predominant Hodgkin’s disease from a clonal expansion of highly mutated germinal-center B cells. The New England Journal of Medicine. 1997;337(7):453–458. [PubMed]
19. Brune V, Tiacci E, Pfeil I, et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. Journal of Experimental Medicine. 2008;205(10):2251–2268. [PMC free article] [PubMed]
20. Nam-Cha SH, Roncador G, Sanchez-Verde L, et al. PD-1, A follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma. American Journal of Surgical Pathology. 2008;32(8):1252–1257. [PubMed]
21. Kraus MD, Haley J. Lymphocyte predominance Hodgkin’s disease: the use of bcl-6 and CD57 in diagnosis and differential diagnosis. American Journal of Surgical Pathology. 2000;24(8):1068–1078. [PubMed]
22. Montes-Moreno S, Roncador G, Maestre L, et al. Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas. Blood. 2008;111(1):351–358. [PubMed]
23. Natkunam Y, Zhao S, Mason DY, et al. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Blood. 2007;109(4):1636–1642. [PubMed]
24. Poppema S. The nature of the lymphocytes surrounding Reed-Sternberg cells in nodular lymphocyte predominance and in other types of Hodgkin’s disease. American Journal of Pathology. 1989;135(2):351–357. [PubMed]
25. Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. American Journal of Surgical Pathology. 2006;30(7):802–810. [PMC free article] [PubMed]
26. Ansel KM, Ngo VN, Hyman PL, et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature. 2000;406(6793):309–314. [PubMed]
27. Nam-Cha SH, Montes-Moreno S, Salcedo MT, Sanjuan J, Garcia JF, Piris MA. Lymphocyte-rich classical hodgkin’s lymphoma: distinctive tumor and microenvironment markers. Modern Pathology. 2009;22(8):1006–1015. [PubMed]
28. Boudová L, Torlakovic E, Delabie J, et al. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood. 2003;102(10):3753–3758. [PubMed]
29. Diehl V, Stein H, Hummel M, Zollinger R, Connors JM. Hodgkin’s lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2003:225–247. [PubMed]
30. Connors JM. State-of-the-art therapeutics: Hodgkin’s lymphoma. Journal of Clinical Oncology. 2005;23(26):6400–6408. [PubMed]
31. Diehl V, Engert A, Re D. New Strategies for the Treatment ofAdvanced-Stage Hodgkin’s Lymphoma. Hematology/Oncology Clinics of North America. 2007;21(5):897–914. [PubMed]
32. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. Journal of Clinical Oncology. 2007;25(24):3746–3752. [PubMed]
33. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-κb-RelA activation is required for proliferation and survival of Hodgkin’s disease tumor cells. The Journal of Clinical Investigation. 1997;100(12):2961–2969. [PMC free article] [PubMed]
34. Carbone A, Gloghini A, Gruss H-J, Pinto A. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin’s disease. American Journal of Pathology. 1995;147(4):912–922. [PubMed]
35. Aldinucci D, Rapana' B, Olivo K, et al. IRF4 is modulated by CD40L and by apoptotic and anti-proliferative signals in Hodgkin lymphoma. British Journal of Haematology. 2010;148(1):115–118. [PubMed]
36. Chiu A, Xu W, He B, et al. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood. 2007;109(2):729–739. [PubMed]
37. Zheng B, Flumara P, Li YV, et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood. 2003;102(3):1019–1027. [PubMed]
38. Fiumara P, Snell V, Li Y, et al. Functional expression of receptor activator of nuclear factor κB in Hodgkin disease cell lines. Blood. 2001;98(9):2784–2790. [PubMed]
39. Joos S, Menz CK, Wrobel G, et al. Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood. 2002;99(4):1381–1387. [PubMed]
40. Martín-Subero JI, Gesk S, Harder L, et al. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood. 2002;99(4):1474–1477. [PubMed]
41. Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT. Mutations in the IkBa gene in Hodgkin’s disease suggest a tumour suppressor role for IκBα Oncogene. 1999;18(20):3063–3070. [PubMed]
42. Emmerich F, Theurich S, Hummel M, et al. Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells. Journal of Pathology. 2003;201(3):413–420. [PubMed]
43. Jungnickel B, Staratschek-Jox A, Bräuninger A, et al. Clonal deleterious mutations in the iκbα gene in the malignant cells in Hodgkin’s lymphoma. Journal of Experimental Medicine. 2000;191(2):395–401. [PMC free article] [PubMed]
44. Kato M, Sanada M, Kato I, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature. 2009;459(7247):712–716. [PubMed]
45. Schmitz R, Hansmann M-L, Bohle V, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. Journal of Experimental Medicine. 2009;206(5):981–989. [PMC free article] [PubMed]
46. Schreck S, Friebel D, Buettner M, et al. Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin Lymphoma. Hematological Oncology. 2009;27(1):31–39. [PubMed]
47. Juszczynski P, Ouyang J, Monti S, et al. The AP1-dependent secretion of galectin-1 by Reed-Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(32):13134–13139. [PubMed]
48. Aldinucci D, Gloghini A, Pinto A, De Filippi R, Carbone A. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. Journal of Pathology. 2010;221(3):248–263. [PubMed]
49. Hsi ED. Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: Tumor and microenvironment. Leukemia and Lymphoma. 2008;49(9):1668–1680. [PubMed]
50. Poppema S. Immunobiology and pathophysiology of Hodgkin lymphomas. Hematology American Society of Hematology Education Program. 2005:231–238. [PubMed]
51. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002;99(12):4283–4297. [PubMed]
52. Yamamoto R, Nishikori M, Kitawaki T, et al. PD-1 PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood. 2008;111(6):3220–3224. [PubMed]
53. Sánchez-Aguilera A, Montalbán C, De La Cueva P, et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood. 2006;108(2):662–668. [PubMed]
54. Kusmartsev S, Gabrilovich DI. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. The Journal of Immunology. 2005;174(8):4880–4891. [PubMed]
55. Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood. 2004;103(5):1755–1762. [PubMed]
56. Riley JL, June CH. The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood. 2005;105(1):13–21. [PubMed]
57. Hirano F, Kaneko K, Tamura H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Research. 2005;65(3):1089–1096. [PubMed]
58. Sanchez-Espiridion B, Montalban C, Lopez A, et al. A molecular risk score based on four functional pathways for advanced classical Hodgkin lymphoma. Blood. 2010;116(8):e12–e17. [PubMed]
59. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. The New England Journal of Medicine. 2010;362(10):875–885. [PMC free article] [PubMed]
60. Coppleson LW, Rappaport H, Strum SB, Rose J. Analysis of the Rye classification of Hodgkin’s disease. The prognostic significance of cellular composition. Journal of the National Cancer Institute. 1973;51(2):379–390. [PubMed]
61. Ree HJ, Kadin ME. Macrophage-histiocytes in Hodgkin’s disease. The relation of peanut-agglutinin-binding macrophage-histiocytes to clinicopathologic presentation and course of disease. Cancer. 1985;56(2):333–338. [PubMed]
62. Colby TV, Hoppe RT, Warnke RA. Hodgkin’s disease: a clinicopathologic study of 659 cases. Cancer. 1982;49(9):1848–1858. [PubMed]

Articles from Advances in Hematology are provided here courtesy of Hindawi Publishing Corporation